Xact Kapitalforvaltning AB purchased a new position in Qiagen NV (NYSE:QGEN) in the first quarter, HoldingsChannel.com reports. The institutional investor purchased 16,100 shares of the company’s stock, valued at approximately $655,000.
Other institutional investors and hedge funds also recently modified their holdings of the company. D. E. Shaw & Co. Inc. lifted its position in Qiagen by 19.8% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,756,276 shares of the company’s stock worth $60,489,000 after buying an additional 290,673 shares during the last quarter. Cornerstone Advisors Inc. bought a new stake in Qiagen in the first quarter worth $44,000. Oppenheimer Asset Management Inc. bought a new stake in Qiagen in the fourth quarter worth $118,000. Geode Capital Management LLC lifted its position in Qiagen by 8.9% in the fourth quarter. Geode Capital Management LLC now owns 584,780 shares of the company’s stock worth $20,145,000 after buying an additional 47,932 shares during the last quarter. Finally, Macquarie Group Ltd. bought a new stake in Qiagen in the fourth quarter worth $1,854,000. Institutional investors own 63.22% of the company’s stock.
QGEN has been the topic of a number of recent analyst reports. Zacks Investment Research lowered Qiagen from a “hold” rating to a “sell” rating in a research note on Tuesday, April 9th. Wolfe Research initiated coverage on Qiagen in a research note on Thursday, May 30th. They issued a “peer perform” rating on the stock. Deutsche Bank reiterated a “buy” rating on shares of Qiagen in a research note on Wednesday, May 8th. Goldman Sachs Group reiterated a “buy” rating on shares of Qiagen in a research note on Tuesday, May 7th. Finally, UBS Group initiated coverage on Qiagen in a research note on Friday, March 15th. They issued a “neutral” rating and a $42.00 target price on the stock. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $41.71.
Shares of Qiagen stock traded up $0.26 during trading on Thursday, hitting $39.54. 36,105 shares of the stock traded hands, compared to its average volume of 1,255,814. The firm has a market cap of $8.79 billion, a P/E ratio of 29.48, a P/E/G ratio of 2.34 and a beta of 0.84. The company has a current ratio of 1.69, a quick ratio of 1.52 and a debt-to-equity ratio of 0.54. Qiagen NV has a 52-week low of $32.33 and a 52-week high of $41.55.
Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Monday, May 6th. The company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.26 by $0.01. The firm had revenue of $348.70 million for the quarter, compared to analyst estimates of $351.68 million. Qiagen had a return on equity of 12.22% and a net margin of 12.45%. The business’s revenue for the quarter was up 1.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.26 earnings per share. Analysts forecast that Qiagen NV will post 1.43 earnings per share for the current year.
WARNING: This story was originally posted by Riverton Roll and is the property of of Riverton Roll. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://rivertonroll.com/news/2019/06/13/xact-kapitalforvaltning-ab-invests-655000-in-qiagen-nv-nyseqgen-stock.html.
Qiagen Company Profile
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Featured Article: What is a Real Estate Investment Trust (REIT)?
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NYSE:QGEN).
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.